Acelyrin Q2 2024 Earnings Report
Key Takeaways
Acelyrin announced positive Phase 3 data for Izokibep in Hidradenitis Suppurativa, met primary endpoint of HiSCR75 at 12 weeks. The company will prioritize the development of Lonigutamab and expects to initiate a Phase 3 program in Q1 2025. Cash, cash equivalents, and short-term marketable securities totaled $635.2 million at June 30, 2024, which is projected to extend the cash runway to mid-2027.
Phase 3 trial of izokibep in hidradenitis suppurativa met primary endpoint of HiSCR75 at 12 weeks.
Company to prioritize development of lonigutamab; dose confirmation ongoing in Phase 2 trial with plans to initiate Phase 3 program in Q1 2025.
Cash, cash equivalents, and short-term marketable securities at June 30, 2024 of $635.2 million; projected to extend cash runway to mid-2027.
ACELYRIN is completing an approximately 33% reduction in its workforce.